Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor

BACKGROUND: Chronic Myeloid Leukemia (CML) is caused by the abnormal fusion protein BCR-ABL1, a constitutively active tyrosine kinase and product of the Philadelphia chromosome. Gleevec (Imatinib mesylate) is a selective inhibitor of this kinase. Treatment with this agent is known to result in hemat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kayastha, Gyan K, Gurung, Padma, Acharya, Paras K, Paudyal, Buddhi P, Hayes, Bruce, Zimmerman, Mark, Karki, Arjun, Mansfield, Aaron S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017013/
https://www.ncbi.nlm.nih.gov/pubmed/21138592
http://dx.doi.org/10.1186/1471-2326-10-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017013/
https://www.ncbi.nlm.nih.gov/pubmed/21138592
http://dx.doi.org/10.1186/1471-2326-10-8

Ejemplares similares